Ixazomib-¹³C₂,¹⁵N

Cat. No.: HY-W748328: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Ixazomib-¹³C₂,¹⁵N is ¹³C and ¹⁵N labeled Ixazomib. Ixazomib (MLN2238) is a selective, potent, and reversible proteasome inhibitor, which inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an IC₅₀ of 3.4 nM (K_i of 0.93 nM).

For research use only. We do not sell to patients.

Ixazomib-<sup>13</sup>C<sub>2</sub>,<sup>15</sup>N Chemical Structure

Ixazomib-¹³C₂,¹⁵N Chemical Structure

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Ixazomib-¹³C₂,¹⁵N:

Ixazomib In-stock

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description	Ixazomib-¹³C₂,¹⁵N is ¹³C and ¹⁵N labeled Ixazomib. Ixazomib (MLN2238) is a selective, potent, and reversible proteasome inhibitor, which inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an IC₅₀ of 3.4 nM (K_i of 0.93 nM)^[1].
Molecular Weight	364.01
Formula	C₁₂¹³C₂H₁₉BCl₂N¹⁵NO₄
Unlabeled CAS	1072833-77-2
SMILES	ClC1=CC(C([15N]([13C]([H])([13C](N[C@H](B(O)O)CC(C)C)=O)[H])[H])=O)=C(C=C1)Cl
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (268 KB) Handling Instructions (2659 KB)
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief] [2]. Friedman JR, et al. Anticancer Activity of Natural and Synthetic Capsaicin Analogs. J Pharmacol Exp Ther. 2018 Mar;364(3):462-473. [Content Brief]